Building synthetic cells to broaden access to advanced diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing. The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. The new funding will enable […]

Emeryville, CA (June 14, 2022) – SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Almog Diagnostic, a private company […]